What is the recommended dose of Movicol (polyethylene glycol 3350 + electrolytes) for children?

Movicol (Polyethylene Glycol 3350 + Electrolytes) Dosing in Children

For pediatric chronic constipation, start with 0.4–0.8 g/kg/day of PEG 3350 (approximately 1 sachet per day for most children), adjusting upward as needed to achieve 2 soft stools daily, with a typical effective maintenance dose of 0.78–0.84 g/kg/day.

Age-Specific Dosing Recommendations

Infants Under 2 Years

• Starting dose: 0.26–0.88 g/kg/day 1
• Effective maintenance dose: 0.78 g/kg/day (range 0.26–1.26 g/kg/day) 1
• Safety profile: PEG 3350 has been demonstrated safe and effective in infants as young as 0–5 months, with similar dose and safety profiles to older children 1
• Duration: Mean treatment duration of 6.2 months has been studied without significant adverse effects 1

Children 2–16 Years

Based on real-world UK data for Movicol Paediatric Plain (PEG 3350 + electrolytes):

• Most common daily dose: 1 sachet (6.9 g PEG 3350) 2
• Dose range by age group (from clinical trial data) 3:
  • 0–2 years: 0.4–2.3 sachets/day
  • 2–4 years: 0.1–3.5 sachets/day
  • 4–8 years: 0.7–3.8 sachets/day
  • 8–16 years: 0.6–3.7 sachets/day

Optimal Maintenance Dosing

• Target dose: 0.84 g/kg/day (range 0.27–1.42 g/kg/day) to achieve 2 soft stools per day 4
• Dose titration: Adjust every 3 days based on stool frequency and consistency 4
• Treatment goal: Increase stool frequency from baseline (typically 2–3 stools/week) to approximately 1 stool per day with soft consistency 3, 4

Disimpaction Protocols

For severe fecal impaction requiring hospitalization:

Combined Oral + Enema Therapy

• Oral dose: 50–70 mL/kg/day of PEG 3350 + electrolyte solution (equivalent to 3–4.1 g/kg/day PEG 3350) 5
• Enema dose: 15–25 mL/kg per dose, 1–2 times daily (equivalent to 0.975–1.625 g/kg/day PEG 3350) 5
• Duration: Typically 2–3 days of combined therapy 5
• Enhanced protocol: Adding sodium picosulphate (stimulant laxative) to PEG 3350 + electrolytes for 2-day disimpaction shows superior efficacy compared to PEG alone 6

Safety Considerations

Adverse Effects Profile

• Common mild effects: Transient diarrhea (3.0%), vomiting (4.1%), abdominal pain (0.5%), increased gas 2, 1
• Resolution: Diarrhea typically resolves with dose adjustment 1
• Electrolyte safety: No abnormal electrolyte values or clinically significant electrolyte disturbances observed in children under 2 years or during high-dose disimpaction protocols 2, 5
• Serious adverse events: No drug-related serious adverse events reported in long-term studies 3

Monitoring

• Electrolytes: Check before and after disimpaction in hospitalized patients receiving high-dose therapy 5
• Stool diary: Monitor frequency, consistency (rated 1–5 scale), and soiling episodes 4
• Dose adjustment: Titrate every 3 days to achieve target of 2 soft stools daily without diarrhea 4

Clinical Efficacy Outcomes

Short-Term Response (8–12 Weeks)

• Stool frequency: Increases from 2.3 stools/week to 16.9 stools/week 4
• Stool consistency: Improves from hard (score 1.2) to soft-formed (score 3.3) 4
• Soiling reduction: Decreases from 10 episodes/week to 1.3 episodes/week in children with encopresis 4
• Response rate: 97.6% of children achieve relief of constipation 1

Long-Term Response (52 Weeks)

• Treatment success: 45–50% of children achieve ≥3 bowel movements per week with <1 episode of fecal incontinence 3
• Symptom improvement: Mean reduction in total symptom score of 3.74–3.81 points 3
• Sustained efficacy: Improvements in stool frequency and consistency maintained through 12 weeks 7

Important Clinical Caveats

• Palatability: PEG 3350 is generally well-tolerated and palatable in children, with high satisfaction rates 4, 1
• Formulation note: The provided FDA label references 8 are for mycophenolate mofetil (an immunosuppressant), not Movicol/PEG, and should be disregarded for this indication
• Duration of therapy: Mean treatment duration in real-world practice is approximately 89 days for first treatment episode, though many children require longer-term maintenance 2
• Dose individualization: While starting doses are standardized, final effective dose varies considerably between patients (0.26–1.42 g/kg/day range) and requires titration 4, 1